Logo Image
Opinion|Videos|June 2, 2025

EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific population.

Episodes in this series

Video content above is prompted by the following:

Clinical Brief: Elacestrant Subgroup Benefits and Safety Profile

Main Discussion Topics:

  • Efficacy across different disease sites (bone-only versus visceral)
  • Impact of tumor burden (multiple sites of metastasis)
  • Co-mutation status (PIK3CA, p53) and treatment efficacy
  • Safety profile focusing on gastrointestinal (GI) tolerability and lipid monitoring
  • FDA recommendation for lipid profile monitoring requirements

Key Points for Physicians:

  • Elacestrant efficacy maintained in visceral disease and high tumor burden
  • Unexpected positive results even in p53-mutant tumors
  • Less antiemetic use required compared with aromatase inhibitors
  • New requirement: lipid profile before treatment and as needed thereafter
  • Overall well-tolerated side effect profile with manageable GI symptoms

The comprehensive subset analyses support broad applicability of elacestrant in ESR1-mutant patients who demonstrate endocrine sensitivity, regardless of traditional adverse prognostic factors.

Related to this article

View more